Solid glp-1 derivative compositions for oral administration
US11167014B2 · kind B2 · utility
3Cited by
8References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 11, 2018 |
| Grant date | Nov 9, 2021 |
| Priority date | — |
| Expiry date | Jun 11, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to solid compositions for oral administration comprising (i) a GLP-1 derivative and the SGLT2 inhibitor dapagliflozin or (ii) a GLP-1 derivative and a salt of NAC in combination with an SGLT2 inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.